MET exon 14 skipping mutations and MET amplification have emerged as critical therapeutic targets in NSCLC, with the development of MET tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and antibody–drug conjugates (ADCs) [11]. This evidence concerns the gene MET and non-small cell lung carcinoma.